Tags

Type your tag names separated by a space and hit enter

Treatment of cutaneous leishmaniasis among travellers.
J Antimicrob Chemother. 2004 Feb; 53(2):158-66.JA

Abstract

Leishmaniasis is endemic in 88 countries on five continents. There are 1-1.5 million cases of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in recorded cases over the last 10 years. Based on geographical distribution, cutaneous leishmaniasis is divided into Old World and New World leishmaniasis. In the past, species could be inferred from geographical setting or determined by performing culture and isoenzyme analysis. The recently developed and now widely available PCR technology allows a rapid diagnosis with determination of most species, and thus enables a species-orientated treatment. While the Old World species mostly cause benign and often self-limiting cutaneous disease, the American species cause a broad spectrum of conditions from benign to severe manifestations, including mucosal involvement. The response to treatment varies according to the species. Therefore, a species-specific approach is proposed. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use and adverse effects. Indications for local or systemic treatment are proposed. Drugs under investigation are also mentioned. An overview of published treatment options and a treatment recommendation is given for each of the most important species. The level of evidence of the studies leading to these recommendations is given.

Authors+Show Affiliations

Swiss Tropical Institute, Socinstrasse 57, 4002 Basel, Switzerland. johannes.blum@unibas.chNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

14729756

Citation

Blum, J, et al. "Treatment of Cutaneous Leishmaniasis Among Travellers." The Journal of Antimicrobial Chemotherapy, vol. 53, no. 2, 2004, pp. 158-66.
Blum J, Desjeux P, Schwartz E, et al. Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother. 2004;53(2):158-66.
Blum, J., Desjeux, P., Schwartz, E., Beck, B., & Hatz, C. (2004). Treatment of cutaneous leishmaniasis among travellers. The Journal of Antimicrobial Chemotherapy, 53(2), 158-66.
Blum J, et al. Treatment of Cutaneous Leishmaniasis Among Travellers. J Antimicrob Chemother. 2004;53(2):158-66. PubMed PMID: 14729756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of cutaneous leishmaniasis among travellers. AU - Blum,J, AU - Desjeux,P, AU - Schwartz,E, AU - Beck,B, AU - Hatz,C, Y1 - 2004/01/16/ PY - 2004/1/20/pubmed PY - 2004/4/21/medline PY - 2004/1/20/entrez SP - 158 EP - 66 JF - The Journal of antimicrobial chemotherapy JO - J Antimicrob Chemother VL - 53 IS - 2 N2 - Leishmaniasis is endemic in 88 countries on five continents. There are 1-1.5 million cases of cutaneous leishmaniasis reported yearly worldwide. There has been a sharp increase in recorded cases over the last 10 years. Based on geographical distribution, cutaneous leishmaniasis is divided into Old World and New World leishmaniasis. In the past, species could be inferred from geographical setting or determined by performing culture and isoenzyme analysis. The recently developed and now widely available PCR technology allows a rapid diagnosis with determination of most species, and thus enables a species-orientated treatment. While the Old World species mostly cause benign and often self-limiting cutaneous disease, the American species cause a broad spectrum of conditions from benign to severe manifestations, including mucosal involvement. The response to treatment varies according to the species. Therefore, a species-specific approach is proposed. Drugs for systemic and topical treatment are presented and discussed with regard to their application, use and adverse effects. Indications for local or systemic treatment are proposed. Drugs under investigation are also mentioned. An overview of published treatment options and a treatment recommendation is given for each of the most important species. The level of evidence of the studies leading to these recommendations is given. SN - 0305-7453 UR - https://www.unboundmedicine.com/medline/citation/14729756/Treatment_of_cutaneous_leishmaniasis_among_travellers_ L2 - https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkh058 DB - PRIME DP - Unbound Medicine ER -